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Abstract 
Background: older adults are frequent users of emergency services and demonstrate high rates of 
adverse outcomes following emergency care. 
Objective: to perform a systematic review and meta-analysis of the Identification of Seniors At Risk 
(ISAR) screening tool, to determine its predictive value in identifying adults ≥65 years at risk of 
functional decline, unplanned emergency department (ED) readmission, emergency hospitalisation or 
death within 180 days after index ED visit/hospitalisation. 
Methods: a systematic literature search was conducted in PubMed, EMBASE, CINAHL, EBSCO and the 
Cochrane Library to identify validation and impact analysis studies of the ISAR tool. A pre-specified 
ISAR score of ≥2 (maximum score 6 points) was used to identify patients at high risk of adverse 
outcomes. A bivariate random effects model generated pooled estimates of sensitivity and specificity. 
Statistical heterogeneity was explored and methodological quality was assessed using validated 
criteria. 
Results: thirty-two validation studies (n = 12,939) are included. At ≥2, the pooled sensitivity of the ISAR 
for predicting ED return, emergency hospitalisation and mortality at 6 months is 0.80 (95% confidence 
interval (CI) 0.70–0.87), 0.82 (95% CI 0.74–0.88) and 0.87 (95% CI 0.75–0.94), respectively, with a 
pooled specificity of 0.31 (95% CI 0.24–0.38), 0.32 (95% CI 0.24–0.41) and 0.35 (95% CI 0.26–0.44). 
Similar values are demonstrated at 30 and 90 days. Three heterogeneous impact analysis studies 
examined the clinical implementation of the ISAR and reported mixed findings across patient and 
process outcomes. 
Conclusion: the ISAR has modest predictive accuracy and may serve as a decision-making adjunct 
when determining which older adults can be safely discharged. 
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Background 
Older adults are the most frequent users of emergency services, accounting for up to 25% of all 
emergency department (ED) attendances [1]. Furthermore, older adults utilise more healthcare 
resources, experience longer ED stays and demonstrate higher rates of adverse outcomes following 
emergency care such as return to ED, emergency or unplanned hospitalisation and death [2, 3]. Early 
detection of older adults at risk of these adverse outcomes through systematic screening in the ED 
setting can serve to identify highrisk groups in need of targeted assessment and early intervention [4, 
5], either in the hospital or in the community setting. 
A number of tools have been developed to identify older adults at high risk of adverse outcomes 
following ED visit. These tools serve to quantify the individual contribution that various components 
of the history, physical examination and basic laboratory results make towards the diagnosis, 
prognosis or likely response to treatment in a patient [6]. The Identification of Seniors At Risk (ISAR) 
screening tool was developed to identify adults ≥65 years at risk of future adverse outcomes including 
functional decline, unplanned hospitalisation or ED visit, nursing home admission or death following 
an index ED visit or hospital inpatient discharge [7]. The tool consists of a six-item self-report screening 
questionnaire with dichotomous yes/no responses. A score of ≥2 points indicates that the person is at 
increased risk of an adverse outcome with reported risk ratios ranging from 2.20 [8] to 3.46 [9]. A 
summary of the rule is presented in (Supplementary data, available in Age and Ageing online). Since 
its derivation, a number of studies have attempted to validate the ISAR rule [7–9, 20–48], with varying 
results. This systematic review and meta-analysis of validation studies of the ISAR serves to summarise 
the totality of evidence regarding the predictive value in identifying older adults at risk of adverse 
outcomes after ED discharge/hospitalisation. A secondary aim is to explore impact analysis studies 
that examine the implementation of the ISAR in clinical practice. 
Methods 
Study design 
This systematic review and meta-analysis was performed according to the principles outlined in the 
Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy [10]. The PRISMA guidelines 
were also referenced [11]. A detailed protocol is contained on our Departmental website 
(www.hrbcentreprimarycare.ie/ OurPublications). 
Search strategy 
A systematic literature search was conducted in September 2015 in PubMed, EMBASE, CINAHL, EBSCO 
and the 
Cochrane Library. We did not seek to identify grey literature as part of this review. A copy of the search 
string is contained in Appendix 2 (Supplementary data, available in Age and Ageing online). This search 
was supplemented by hand searching references of retrieved papers and searching Google Scholar. 
Study selection and data extraction 
Validation studies 
Prospective or retrospective cohort study in a hospital setting that attempted to validate the ISAR in 
older adults following ED discharge/hospitalisation and recorded individual or composite outcomes 
including functional status/ decline, unplanned return to ED, emergency hospitalisation, nursing home 
admission or death within 6 months after index visit. 
Impact analysis 
Randomized (cluster) controlled trials, controlled before– after studies or interrupted time series 
studies where the ISAR tool was used to screen older adults at high risk of adverse outcomes and a 
subsequent intervention was compared to usual care in the clinical setting were included. Outcomes 
included process of care such as number of inpatient bed days, patient outcomes, clinician behaviour 
and/or cost-effectiveness. 
Two reviewers (Y.G., R.G.) independently read the titles and/or abstracts of the identified papers and 
eliminated irrelevant studies. Studies considered to be eligible for inclusion were read in full and their 
suitability for inclusion was determined independently by two reviewers (Y.G., R.G.). Disagreements 
were managed by consensus. 
Quality assessment 
Quality assessment was independently performed by two reviewers (Y.G., R.G.). Validation studies 
were assessed using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool [12]. 
Each impact analysis study was assessed using the Cochrane risk of bias tool [13] for randomised 
controlled trials (RCTs) and Cochrane criteria for controlled before–after studies [14]. Disagreement 
was managed by a third reviewer (E.W.). 
Statistical analysis 
Statistical analysis was conducted using Stata version 12 (StataCorp, TX, USA). We constructed 2 × 2 
tables (ISAR ≥2) and extracted the number of true positives, false positives, true negatives and false 
negatives from each study for each outcome at 30, 90 and 180 days. Authors were contacted to 
provide additional data on study outcomes where necessary. Summary estimates of sensitivity and 
specificity with 95% confidence intervals (95% CIs) were calculated using the bivariate random effects 
model. We have employed this methodology in previous studies [15–17]. Sensitivity refers to the 
proportion of older adults who experience an adverse outcome correctly classified as high risk (ISAR 
≥2) whereas specificity refers to those who do not experience an adverse outcome correctly classified 
as low risk (ISAR <2). In clinical practice, screening tools with high sensitivity are preferable to safely 
‘rule-out’ those at low risk of a subsequent adverse outcome (as opposed to diagnostic tools that 
generally demonstrate high specificity). 
Individual and summary estimates of sensitivity and specificity were plotted on a receiver-operating 
characteristic (ROC) graph. Statistical heterogeneity was explored using the variance of logit-
transformed sensitivity and specificity, with smaller values suggesting less heterogeneity between 
studies. Bayes’ theorem was applied to estimate the post-test probability of an adverse outcome [18]. 
The c statistic, or area under the curve, with 95% CI describes model discrimination. Values between 
0.7 and 0.9 represent moderate accuracy and values greater than 0.9 represent high accuracy [19]. 
We performed sensitivity analyses to examine the impact of methodological quality on the predictive 
value of the ISAR. 
Results 
Study identification 
A flow diagram of the search strategy is presented in Figure 1. A total of 32 studies attempted to 
validate the ISAR and comprised 25 unique patient cohorts [7–9, 20–48]. The remaining seven articles 
reported on different outcomes using data from existing databases [22, 23, 25, 29,30 36, 43]. Three 
original studies that conducted impact analyses of the ISAR tool were also identified and are reported 
separately [49–51]. 
Study characteristics and quality 
  
Figure 1. Flow of studies in the review. 
Appendix 3 (Supplementary data, available in Age and Ageing online) summarises the characteristics 
of the 32 studies conducted across Europe, North America, Central  
America and Asia. Studies ranged in sample size from 83 [30] to 2,057 participants [34]. Twelve studies 
included a combination of patients who were both discharged and hospitalised after the index ED visit 
[7–9, 22, 25 ,27, 29, 33, 34, 40, 41, 48], 11 studies only included patients that were discharged 
following ED visit [20, 21, 23, 26, 28, 30– 32, 39, 42, 46] and 9 included only hospitalised patients [24, 
35–38, 43–45, 47]. The duration of follow-up varied from 14 days [30, 31, 35, 36] to 12 months [32, 
47], with outcomes at 30 and 90 days the most commonly reported follow-up periods. Additional 
unpublished data were provided by ten authors [8, 26, 28, 37, 38, 42, 45, 47, 48]. In total, 12,939 
patients were included in the meta-analysis. A summary of the methodological quality of studies is 
displayed in Table 1. 
Predictive accuracy of the ISAR for adverse outcomes at 30 days, 3 and 6 months 
At 6 months, the sensitivity of an ISAR score of ≥2 for predicting ED return, emergency hospitalisation 
and mortality is 0.80 (95% CI 0.70–0.87), 0.82 (95% CI 0.74–0.88) and 0.87 (95% CI 0.75–0.94) 
respectively, with a specificity of 0.31 (95% CI 0.24–0.38), 0.32 (95% CI 0.24–0.41) and 0.35 (95% CI 
0.26–0.44). There are inadequate data available to perform an analysis on functional decline. At 30 
days, pooled estimates of sensitivity at a cut-point of ≥2 are 0.81 (95% CI 0.73–0.87) for ED return, 
0.83 (95% CI 0.75–0.90) for hospitalisation, 0.91 (95% CI 0.80–0.96) for functional decline and 0.97 
(95% CI 0.89–0.99) for mortality. The pooled sensitivity, specificity and the respective variance of the 
logit-transformed sensitivity and specificity for each outcome at 30 days, 3 and 6 months are 
presented in Table 2. These pooled estimates demonstrate that the ISAR has modest predictive 
accuracy as a screening tool, with a consistently high sensitivity (≥80% for all outcomes) and a 
moderate to low specificity across all outcomes and time points. Statistical heterogeneity across 
studies is low, reflected in the values for the variance of logit-transformed sensitivity and specificity 
(Table 2). Appendix 4 (Supplementary data, available in Age and Ageing online) illustrates the 
summary ROC curves for all outcomes across all time points. Summary estimates are broadly similar 
when we performed a sensitivity analysis excluding the studies with evidence of spectrum bias (see 
Supplementary data, Appendix 5, available in Age and 
Ageing online). 
Bayesian analysis 
Using Bayes theorem, the pre-test and post-test probability of adverse outcomes at 30 days, 3 and 6 
months is presented in Table 3. At 6 months, an ISAR score of <2 predicts a lower probability of ED 
return from 33% to 25%, emergency hospitalisation from 32% to 21% and mortality by almost two-
thirds (from 11% to 4%). At 3 months, a score of <2 almost halves the probability of an ED return (from 
30% to 16%) and mortality (from 7% to 3%). Consistent with modest values for sensitivity when 
compared with low values for specificity, the c statistic is 
  
Table 1. Methodological quality of the studies included in the review 
  Risk of bias Applicability concerns 
 Patient selection Index test Reference standard Flow and timing Patient 
selection Index test Reference standard 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Asomaning 2013 Unclear Unclear Unclear Low Low Low Low 
Braes 2009 Low Low Unclear Low Low Low Low 
Braes 2010 Low Low Unclear Low Low Low Low 
Buurman 2011 Low Low Unclear Low Low Low Low 
De Saint-Hubert 2010 Low High Unclear Low High Low Low 
Dendukuri 2004 Low Low Unclear Low Unclear Low Low 
Deschodt 2011 Low Low Unclear Low Low Low Low 
Di Bari 2012 Low Low Unclear Low Low Low Low 
Edmans 2013 Low Low Unclear Low Low Low Low 
Geyskens 2008 Low Low Unclear Low Low Low Low 
Graf 2012 High Unclear Unclear Low High Low Low 
Heim 2015 Low Low Unclear Low High Low Low 
Hoogerduijn 2010 Low Low Unclear Low Low Low Low 
McCusker 1999 Low Low Unclear Low Low Low Low 
McCusker, Bellavance 2000 Low Low Unclear Low Low Low Low 
McCusker, Cardin 2000 Low Low Unclear Low Low Low Low 
Moons 2007 Low Low Unclear Low Low Low Low 
Rosted 2014 Unclear Low Low Low Low Low Low 
Salvi 2009 Low Low Unclear Low Low Low Low 
Salvi 2012 Low Low Unclear Low Low Low Low 
Salvi, Morichi, Grilli 2012 Low Low Unclear Low Low Low Low 
Singler 2014 Low Low Unclear Unclear Low Low Low 
Sirois 2013 Low Low Unclear Low High Low Low 
Suffoletto 2016 Low Low Low Low Low Low Low 
Yim 2011 Unclear Low Unclear Low Unclear Unclear Low 
  
Table 2. Summary estimates of sensitivity and specificity for all studies 
  
Outcome Number of studies Number of patients Sensitivity 95% CI Variance 
logit (sensitivity) Specificity 95% CI Variance logit (specificity) 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Functional decline 
 30 days 4 1,237 0.91 0.80–0.96 0.56 0.27 0.19–0.37 0.17 
3 months 9 2,328 0.83 0.77–0.88 0.14 0.34 0.28–0.41 0.13 
ED return 
30 days 10 4,328 0.81 0.73–0.87 0.40 0.29 0.22–0.38 0.35 
3 months 5 1,090 0.84 0.73–0.91 0.39 0.38 0.29–0.48 0.17 
6 months 5 4,485 0.80 0.70–0.87 0.36 0.31 0.24–0.38 0.14 
Hospitalisation 
30 days 9 2,716 0.83 0.75–0.90 0.52 0.26 0.19–0.34 0.32 
3 months 6 1,814 0.80 0.70–0.87 0.33 0.38 0.30–0.46 0.14 
6 months 5 4,484 0.82 0.74–0.88 0.27 0.32 0.24–0.41 0.17 
Mortality 
30 days 6 2,152 0.97 0.89–0.99 0.58 0.24 0.16–0.34 0.41 
3 months 6 2,338 0.85 0.72–0.92 0.55 0.37 0.29–0.45 0.15 
6 months 5 5,808 0.87 0.75–0.94 0.76 0.35 0.26–0.44 0.19 
Table 3. Bayesian analysis for all studies       
Outcome Pre-test probability Positive LR Post-test probability Negative LR
 Post-test probability c statistic 
 % (95% CI) (95% CI) % Positive LR (95% CI) % Negative LR (95% CI) 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Functional decline 
30 days 36.9 (34.3–39.7) 1.34 (1.09–1.40) 43.9 (36.3–48.0) 0.35 (0.16–0.77)
 17.0 (7.7–33.6) 0.55 (0.51–0.59) 
3 months 
ED return 24.4 (22.7–26.2) 1.26 (1.15–1.39) 28.9 (25.2–33.0) 0.49 (0.37–
0.67) 13.7 (9.8–19.2) 0.65 (0.61–0.69) 
30 days 17.2 (16.1–18.3) 1.15 (1.06–1.24) 19.3 (16.9–21.7) 0.65 (0.50–0.84)
 11.9 (8.8–15.8) 0.58 (0.54–0.62) 
3 months 30.0 (27.4–32.8) 1.35 (1.23–1.49) 36.7 (31.7–42.1) 0.43 (0.30–
0.62) 15.6 (10.2–23.2) 0.62 (0.57–0.66) 
6 months 
Hospitalisation 33.3 (31.9–34.7) 1.15 (1.12–1.20) 36.5 (34.4–38.9) 0.65 (0.51–
0.82) 24.5 (19.3–30.3) 0.51 (0.46–0.55) 
30 days 18.4 (17.0–19.9) 1.13 (1.06–1.20) 20.3 (17.8–23.0) 0.63 (0.48–0.84)
 12.4 (9.0–17.3) 0.54 (0.50–0.58) 
3 months 27.8 (25.8–29.9) 1.28 (1.16–1.42) 33.0 (28.7–37.7) 0.53 (0.38–
0.75) 16.9 (11.7–24.2) 0.58 (0.54–0.62) 
6 months 
Mortality 32.2 (30.9–33.6) 1.20 (1.11–1.30) 36.3 (33.2–39.7) 0.57 (0.44–
0.74) 21.3 (16.4–27.4) 0.58 (0.54–0.62) 
30 days 6.1 (5.2–7.2) 1.29 (1.12–1.48) 7.7 (5.8–10.3) 0.12 (0.02–0.57) 0.8 (0.1–
4.2) 0.80 (0.76–0.83) 
3 months 7.1 (6.1–8.2) 1.34 (1.23–1.45) 9.3 (7.4–11.5) 0.42 (0.25–0.71) 3.1 
(1.6–6.0) 0.57 (0.53–0.62) 
6 months 11.0 (10.2–11.8) 1.34 (1.24–1.44) 14.2 (12.3–16.2) 0.37 (0.22–
0.62) 4.4 (2.4–7.7) 0.57 (0.53–0.61) 
  
  
consistently low, falling below the threshold for moderate discrimination (c statistic 0.7–0.9), except 
in the case of mortality at 30 days. 
Impact analysis of the ISAR tool in a clinical setting 
Three studies examined the impact of the ISAR rule on process of care and patient outcomes [49–51]. 
Appendix 6 (Supplementary data, available in Age and Ageing online) contains the descriptive 
characteristics of these studies. In 2001, McCusker et al. conducted a quasi-randomised controlled 
trial (RCT) where patients ≥65 years who screened ISAR positive (≥2) were randomly assigned to either 
usual care (n = 178) or a brief intervention (n = 210). The intervention consisted of standardised 
nursing assessment in the ED and preparation of a discharge plan that attempted to optimise the use 
of appropriate multidisciplinary outpatient and community services [51]. The intervention was 
associated with a significantly reduced rate of functional decline or death at 4 months (odds ratio (OR) 
= 0.53, 95% CI = 0.31–0.91). There were no significant effects on depressive symptoms or caregiver 
physical or mental health scores. Edmans et al. [49] conducted an RCT including 433 patients aged ≥70 
years screened as high risk (score ≥2) by the ISAR who were discharged within 72 h of attending an 
acute medical assessment unit (AMU). The intervention consisted of an initial assessment by a 
geriatrician in the AMU and further outpatient management by geriatricians, including advice and 
increased support to primary care services. Follow-up at 90 days demonstrated no significant 
differences between groups regarding the length of time to readmission or use of secondary or long-
term care services [49]. Finally, Warburton et al. [50] conducted a controlled before–after study in 277 
patients aged ≥75 years. Thirty-eight patients screened as high risk by ISAR were referred for a specific 
‘Elder Alert’ intervention that incorporated a care plan for appropriate intervention and targeted, 
coordinated, preventive, community-based services. Outcomes at 30 days indicate signficantly lower 
emergency hospital admission rates in the intervention group when compared with the ISAR high-risk 
group who did not receive the intervention (P < 0.05). The methodological quality of these studies in 
described in Appendix 7 (Supplementary data, available in Age and Ageing online). 
Discussion 
Statement of principal findings 
This systematic review and meta-analysis demonstrates that the ISAR has modest predictive accuracy 
as a screening tool in the ED, with high pooled estimates of sensitivity (≥80% for all outcomes) across 
all time points. An ISAR score of <2 predicts a lower probability of ED return, emergency hospitalisation 
within 6 months following ED visit. Three impact analysis studies were identified where the ISAR was 
used to screen high-risk older adults for targeted geriatric interventions. Findings across patient and 
process outcomes were varied between the studies, indicating the need for further evaluation of the 
ISAR rule and subsequent targeted interventions in clinical practice. 
Results in the context of previous studies 
Research indicates that the ISAR tool is the most commonly used screening tools to identify older 
adults at risk of functional decline in the ED [52, 53]. Our findings are at odds with a recent systematic 
review by Carpenter et al. [54] that analysed the predictive value of tools for predicting ED return, 
hospital readmission and functional decline in older adults following ED discharge. Three screening 
instruments were examined in the meta-analysis including the ISAR, the Triage Risk Screening Tool 
and Variables Indicative of Placement Risk. Findings indicated that none of the tools significantly 
increased or decreased the risk of subsequent adverse outcomes [54]. The contrast between our 
findings and those in this earlier review may be explained by the differing methods used to identify 
and pool studies. We identified and included data from 32 studies in our review, versus 18 studies in 
the former review [54]. Moreover, we used individual patient data rather than aggregate data to 
calculate summary estimates of sensitivity and specificity, allowing for a more accurate data analysis 
by accounting for heterogeneity between studies and influences of sample size. 
Two recent reviews of other models to predict hospital admission from the community [55] and 
readmission [56] reported poor performance of included models overall. By comparison, we found 
that the ISAR performs reasonably well, as usually sensitivity for any model predicting an outcome as 
unpredictable as return ED visit and/or emergency admission is quite low. However, care is needed 
when applying such measures in clinical practice as the ISAR tool contains questions that may be 
affected by the older adults’ current health status and state of distress, such as cognition and ability 
to manage activities of daily living. 
Three impact analysis studies were included where the ISAR was used to screen high-risk older adults 
for targeted geriatric interventions. All interventions comprised comprehensive geriatric assessment 
(CGA) and findings across patient and process outcomes varied across studies. A systematic review of 
five RCTs examined the impact of CGA interventions on outcomes in frail older adults discharged from 
acute hospital within 72 h following index ED visit [57] and found no clear evidence in support of CGA 
interventions in terms of mortality [risk ratio (RR) 0.92 (95% CI 0.55–1.52)], readmissions [RR 0.95 
(95% CI 0.83–1.08)] or for subsequent institutionalisation, functional status, quality of life or cognition 
[57]. Another approach that has been explored is the roll out of intensive case-based management 
community interventions in those deemed at high risk of adverse outcomes. However, a recent 
systematic review and meta-analysis of 36 studies of community-initiated case management for adults 
with chronic medical conditions concluded that this intervention is not effective in reducing either 
primary or secondary care healthcare utilisation [58]. 
Strengths and weaknesses 
Data were pooled from 32 studies in 12 different countries across four continents, enhancing the 
generalizability of the findings. We used individual patient data rather than aggregate data to calculate 
summary estimates of sensitivity and specificity. This allowed for more accurate data analysis by 
accounting for heterogeneity between studies and the influences of sample size. However, we were 
unable to explore the predictive accuracy of different cut-points of the ISAR as we did not have access 
to individual patient ISAR scores that mapped to the occurrence/non-occurrence of subsequent 
adverse outcomes. In addition, the ISAR was derived to screen all ED patients either hospitalised or 
discharged after an ED visit and for the purpose of completeness we included studies examining both 
populations either individually or as a composite group in our review. However, not enough data were 
available in the studies to perform a separate analysis on discharged and hospitalised patients as 
individual cohorts. Furthermore, the majority of studies only enrolled patients on weekdays during 
daytime hours and 10 of the 32 studies included older adults’ with age categories other than those 
≥65 years, including cut-offs of ≥75 years (n = 7), ≥70 years (n = 2) and ≥60 years (n = 1), which may 
have resulted in selection bias. However, it was not possible to complete a separate analysis on these 
studies. 
Clinical implications and areas for further research 
This review demonstrates that the incidence of ED return among older adults in the first 6 months 
following index visit is high at 33%. Given the complex needs and clinical presentations of these 
patients combined with time pressures and the need to maintain rapid patient turnover, optimal 
assessment and discharge planning for older adults in ED and hospital settings is a complex and 
challenging process. Screening tools capable of identifying patients at high risk of adverse events have 
the potential to improve patient care by assisting clinicians in the management of these patients. Our 
findings that an ISAR score of <2 indicates a lower probability of ED return, emergency hospitalisation 
within 6 months following ED visit suggests that the ISAR may be considered to be a useful screening 
tool in clinical practice. It also has the advantage of being easy to administer and score which adds to 
its clinical utility in the busy ED setting. However, modifications to the six component questions in the 
ISAR should also be explored. For example, one question included in the ISAR tool is the use of ≥3 
medications which is not the typical definition of polypharmacy in current clinical practice. Salvi et al. 
[9] reported that 77% of their population were taking ≥3 medications. In terms of improving the 
sensitivity of the tool, modifications to this question such as use of ≥5 medications may be more 
appropriate in clinical reality. In addition, the weighted contribution of the six questions warrants 
further investigation through the exploration of the estimated multivariable regression coefficients. 
Given the complexity of the clinical issues related to the care of vulnerable older people, all screening 
tools need to be used as an adjunct to clinical decision-making [21]. Identification of high-risk older 
people is a first step but needs to be supplemented by interventions that are effective in reducing 
adverse outcomes for these patients. To date, there is limited evidence for any single approach in 
achieving this aim but research is ongoing and based on the current literature multifaceted 
interventions designed taking the contextual factors of the local healthcare system into account are 
most likely to be successful [55, 56]. 
Conclusion 
The ISAR has modest predictive accuracy as a screening tool in the ED, with consistently high pooled 
sensitivity estimates across all outcomes and time points. It may serve as a useful adjunct in clinical 
decision-making when determining which older adults can be safely discharged from the ED. 
  
Key points 
• Older adults are the most frequent users of emergency services and have higher rates of 
adverse outcomes following ED visit. 
• The ISAR has modest predictive accuracy as a screening tool for adverse outcomes within 6 
months following ED visit. 
• An ISAR score of <2 predicts a lower probability of ED return, emergency hospitalisation and 
mortality within 6 months. 
• The ISAR may be useful as an adjunct to clinical decisionmaking when determining which older 
adults can be safely discharged. 
  
Supplementary data 
Supplementary data mentioned in the text are available to subscribers in Age and Ageing online 
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